Comparative bioavailability and in-vitro antimicrobial activity of two different brands of rifampicin

Garg, Shubha; Chakrabarti, Amitava; Panigrahi, D; Sharma, Mahima; Talwar, P; Kumar, Nitin; Sharma, P. L.

doi:10.1007/bf03189964

Cited by 4 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of present bioequivalence study support the results of several former studies showing large inter‐individual variability in rifampicin bioavailability (3, 5). The AUC values of different volunteers differed more than three‐fold.…”

Section: Discussionsupporting

confidence: 89%

“…The main rifampicin products in Estonia were Rifampicin from Belmedpreparaty, Belorussia (RB) and Rifampicin, Lupin Laboratories Ltd, India (RL). In our preparatory literature survey we were unable to find any data about RB; one bioequivalence study of RL has been published but in this experiment the drug of comparison was a new unknown generic preparation (5). The aim of the present study was to compare the relative bioavailabilities of two generic rifampicin preparations, RB and RL, with that of Rimactane (Ciba‐Geigy Ltd, Switzerland).…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Comparative bioavailability of three different preparations of rifampicin

et al. 1999

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 98%

Comparative bioavailability of three different preparations of rifampicin

et al. 1999

View full text Add to dashboard Cite

show abstract

“…HPLC was used to measure rifampicin levels in 66 of the 70 studies. The remaining studies used spectrophotometry 33–35 or a plate diffusion assay. 36 These three studies were retained in the meta-analysis because their exclusion did not significantly impact overall PK parameter estimates.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, we were not able to consider the impact of covariates that were not consistently measured on heterogeneity in PK estimates. These included co-medications and associated drug–drug interactions, specific formulations of rifampicin that have been demonstrated to exhibit altered PK, 33 , 45 , 46 and patient ethnicity.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis

Stott

Pertinez

Sturkenboom

et al. 2018

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

ObjectivesThe objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages and to compare these with summary estimates for higher dosages. MethodsA systematic search was performed for studies of rifampicin PK published in the English language up to May 2017. Data describing the Cmax and AUC were extracted. Meta-analysis provided summary estimates for PK parameter estimates at standard rifampicin dosages. Heterogeneity was assessed by estimation of the I2 statistic and visual inspection of forest plots. Summary AUC estimates at standard and higher dosages were compared graphically and contextualized using preclinical pharmacodynamic (PD) data.ResultsSubstantial heterogeneity in PK parameters was evident and upheld in meta-regression. Treatment duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L (SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mg·h/L (SEM 2.60) and 38.73 mg·h/L (SEM 4.33) after single and steady-state dosing, respectively. Rifampicin dosages of at least 25 mg/kg are required to achieve plasma PK/PD targets defined in preclinical studies.ConclusionsVast inter-study heterogeneity exists in rifampicin PK parameter estimates. This is not explained by the available modifying variables. The recommended dosage of rifampicin should be increased to improve efficacy. This study provides an important point of reference for understanding rifampicin PK at standard dosages as efforts to explore higher dosing strategies continue in this field.

show abstract